Urology

Search results

• Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer

  Matthew Galsky,

  14/02/19 → 15/02/19

  4 items of Media coverage

  Press/Media

• Immunotherapy Combination Generates Responses Against Castration-Resistant Metastatic Prostate Cancer

  Matthew Galsky,

  14/02/19 → 15/02/19

  2 items of Media coverage

  Press/Media

• Article of the week: WATER II (80–150 mL) procedural outcomes

  Jay Motola, & Steven Kaplan,

  23/01/19 → 24/01/19

  2 items of Media coverage

  Press/Media

• Ashutosh Tewari Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who's Who

  Ashutosh Tewari

  5/12/18 → 8/12/18

  2 items of Media coverage

  Press/Media

• Congress Must Resist Hospitals' Efforts Against Site-Neutral Payments

  Deepak Kapoor,

  25/10/18

  1 item of Media coverage

  Press/Media

• Congress Must Stick With Site-Neutral Payments

  Deepak Kapoor,

  25/10/18

  1 item of Media coverage

  Press/Media

• Mount Sinai Health System Appoints Peter Wiklund as Director of Bladder Cancer Program

  Peter Wiklund

  7/10/18

  1 item of Media coverage

  Press/Media

• Mount Sinai Health System appoints bladder cancer program director

  Peter Wiklund

  7/10/18

  1 item of Media coverage

  Press/Media

• H + H rolls out five-point plan to transform ambulatory care, stop patient defections

  Joseph Martz & Peter Wiklund

  3/10/18

  1 item of Media coverage

  Press/Media

• Peter Wiklund, MD, PhD, Appointed Director of the Bladder Cancer Program at Mount Sinai

  Peter Wiklund

  3/10/18

  1 item of Media coverage

  Press/Media

• H+H rolls out five-point plan to transform ambulatory care, stop patient defections

  Joseph Martz & Peter Wiklund

  3/10/18

  1 item of Media coverage

  Press/Media

• Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort

  Ketan Badani,

  2/10/18

  1 item of Media coverage

  Press/Media

• Immune Monitoring on Sipuleucel-T; PROVENGE

  Matthew Galsky,

  2/10/18

  1 item of Media coverage

  Press/Media

• The Circulating Cell-free Genome Atlas Study; CCGA

  William Oh

  2/10/18

  1 item of Media coverage

  Press/Media

• Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

  Matthew Galsky,

  2/10/18

  1 item of Media coverage

  Press/Media

• Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

  Matthew Galsky,

  2/10/18

  1 item of Media coverage

  Press/Media

• Metformin for Rising PSA Remote Trial; M-RePoRT

  Matthew Galsky, & Che-Kai Tsao

  2/10/18

  1 item of Media coverage

  Press/Media

• Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

  William Oh

  2/10/18

  1 item of Media coverage

  Press/Media

• A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

  William Oh

  2/10/18

  1 item of Media coverage

  Press/Media

• Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer; CheckMate901

  Matthew Galsky,

  2/10/18

  1 item of Media coverage

  Press/Media

• MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

  Michael Gorin

  2/10/18

  1 item of Media coverage

  Press/Media

• Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

  Matthew Galsky,

  2/10/18

  1 item of Media coverage

  Press/Media

• Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

  Matthew Galsky,

  2/10/18

  1 item of Media coverage

  Press/Media

• Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

  Matthew Galsky,

  2/10/18

  1 item of Media coverage

  Press/Media

• Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

  Matthew Galsky,

  2/10/18

  1 item of Media coverage

  Press/Media